Alector Inc ALEC:NASDAQ

Last Price$15.54NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$15.64 (5)
Ask (Size)$16.50 (2)
Day Low / HighN/A - N/A
Volume557.4 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Alector Inc ( NASDAQ )

Price: $15.54
Change: -0.19 (1.21%)
Volume: 557.4 K
4:00PM ET 1/21/2022
 
 

FibroGen Inc ( NASDAQ )

Price: $13.82
Change: +0.33 (2.45%)
Volume: 3.8 M
4:00PM ET 1/21/2022
 
 

Editas Medicine Inc ( NASDAQ )

Price: $18.15
Change: -0.64 (3.41%)
Volume: 2.8 M
4:00PM ET 1/21/2022
 
 

Atara Biotherapeutics Inc ( NASDAQ )

Price: $13.99
Change: -0.32 (2.24%)
Volume: 1.0 M
4:00PM ET 1/21/2022
 
 

Celldex Therapeutics Inc ( NASDAQ )

Price: $27.87
Change: -1.29 (4.42%)
Volume: 686.7 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Insider Sell: Alector
6:14AM ET 12/15/2021 MT Newswires

Shehnaaz Suliman, President and Chief Operating Officer, on December 10, 2021, sold 150,000 shares in Alector (ALEC) for $3,225,316. Following the Form 4...

Insider Sell: Alector
6:31AM ET 11/15/2021 MT Newswires

Arnon Rosenthal, Director, Chief Executive Officer, on November 10, 2021, sold 110,000 shares in Alector (ALEC) for $2,750,000. Following the Form 4 filing...

Alector Shares AL001 Phase 2 Trial Results
3:03PM ET 11/12/2021 MT Newswires

Alector (ALEC) said Friday that its phase 2 clinical trial of AL001 showed that progranulin, a key regulator of immune activity in the brain, was restored...

Insider Sell: Alector
6:47AM ET 11/11/2021 MT Newswires

Arnon Rosenthal, Director, Chief Executive Officer, on November 08, 2021, sold 200,000 shares in Alector (ALEC) for $5,000,000. Following the Form 4 filing...

Company Profile

Business DescriptionAlector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. View company web site for more details
Address131 Oyster Point Boulevard
South San Francisco, California 94080
Phone+1.415.231.5660
Number of EmployeesN/A
Recent SEC Filing01/05/20224
Chief Executive Officer & DirectorArnon Rosenthal
President, Head-Research & DevelopmentSaraswati Kenkare-Mitra
Chief Financial & Accounting OfficerLinda M. Rubinstein
VP-Technology & Digital HealthCharles Wolfus

Company Highlights

Price Open$15.51
Previous Close$15.73
52 Week Range$15.04 - 43.32
Market Capitalization$1.3 B
Shares Outstanding81.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.52
Beta vs. S&P 500N/A
Revenue$27.7 M
Net Profit Margin-16.62%
Return on Equity-12.96%

Analyst Ratings as of 11/24/2021

Buy
8
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset